NovaSom Inc has appointed Ron Loeppke, MD, a national expert in preventive and occupational health, to its board of directors. His new role will offer strategic guidance to NovaSom as it partners with employers to increase diagnosis and treatment of OSA, a condition that affects over 40 million Americans.

“Dr Loeppke is a terrific addition to our Board as we enhance our focus on working with employers on the early detection of OSA, one of the most serious and underdiagnosed conditions in the United States,” said Richard Hassett, MD, CEO, NovaSom. “He has a strong track record of helping deliver chronic condition and population health management services that improve health outcomes while reducing health care costs. Employers large and small today are aiming to optimize their sleep diagnosis and therapy continuum to achieve more present, productive employees.”

Loeppke has over 30 years of clinical and executive experience in preventive medicine and managing health issues in the workplace. He currently serves as vice-chairman of US Preventive Medicine, a company focused on preventive health care to improve health and reduce costs. Prior, Loeppke held executive roles at organizations including Alere Medical and PHYCOR Inc, where he worked directly with employers and health plans on initiatives to enhance employee health and productivity.

“Employers bear much of the burden of escalating health care costs, and empowering them with the tools to directly diagnose and treat serious diseases such as sleep apnea, which is associated with a host of other dangerous health conditions, is a compelling preventive care model for the future,” Loeppke said.